Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 20.
doi: 10.1038/s41586-025-09411-2. Online ahead of print.

Axonal injury is a targetable driver of glioblastoma progression

Affiliations

Axonal injury is a targetable driver of glioblastoma progression

Melanie Clements et al. Nature. .

Abstract

Glioblastoma (GBM) is an aggressive and highly therapy-resistant brain tumour1,2. Although advanced disease has been intensely investigated, the mechanisms that underpin the earlier, likely more tractable, stages of GBM development remain poorly understood. Here we identify axonal injury as a key driver of GBM progression, which we find is induced in white matter by early tumour cells preferentially expanding in this region. Mechanistically, axonal injury promotes gliomagenesis by triggering Wallerian degeneration, a targetable active programme of axonal death3, which we show increases neuroinflammation and tumour proliferation. Inactivation of SARM1, the key enzyme activated in response to injury that mediates Wallerian degeneration4, was sufficient to break this tumour-promoting feedforward loop, leading to the development of less advanced terminal tumours and prolonged survival in mice. Thus, targeting the tumour-induced injury microenvironment may supress progression from latent to advanced disease, thereby providing a potential strategy for GBM interception and control.

PubMed Disclaimer

Conflict of interest statement

Competing interests: S.P. and C.S.H. are listed as inventors on a PCT patent application (PCT/EP2025/065937) related to the use of WD inhibitors in brain cancer filed by University College London based on the results of this study. The other authors declare no competing interests.

References

    1. McKinnon, C., Nandhabalan, M., Murray, S. A. & Plaha, P. Glioblastoma: clinical presentation, diagnosis, and management. Brit. Med. J. 374, n1560 (2021). - PubMed
    1. Qazi, M. A. et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann. Oncol. 28, 1448–1456 (2017). - PubMed
    1. Hill, C. S., Coleman, M. P. & Menon, D. K. Traumatic axonal injury: mechanisms and translational opportunities. Trends Neurosci. 39, 311–324 (2016). - PubMed - PMC
    1. Coleman, M. P. & Hoke, A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat. Rev. Neurosci. 21, 183–196 (2020). - PubMed - PMC
    1. Bergo, E. et al. Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature. Eur. J. Cancer Care 28, e12410 (2019).

LinkOut - more resources